XOMA Royalty (XOMA) Equity Average (2011 - 2026)
XOMA Royalty's (XOMA) quarterly Equity Average came in at $88.4 million in Q1 2026, up 39.76% year-on-year from $63.3 million in Q1 2025, and up 2.87% quarter-over-quarter from $85.9 million in Q4 2025.
XOMA Royalty (XOMA) Equity Average (2011 - 2026) Analysis & Trends
XOMA Royalty has disclosed Equity Average across 16 years of filings, most recently posting $88.4 million for Q1 2026.
- Equity Average for Q1 2026 came in at $88.4 million, up 39.76% year-over-year; the trailing twelve-month figure through Mar 2026 was $88.4 million (up 39.76% YoY), and the FY2025 annual result was $72.9 million, up 11.67% from the prior year.
- Equity Average came in at $88.4 million for Q1 2026 at XOMA Royalty, up from $85.9 million in the prior quarter.
- In the past five years, Equity Average ranged from a high of $140.9 million in Q1 2022 to a low of $63.3 million in Q1 2025.
- The 5-year median for Equity Average is $87.3 million (2023), against an average of $95.5 million.
- Across the five-year window, Equity Average surged 67.59% in 2022 and sank 45.07% in 2024, its largest moves.
- XOMA Royalty's Equity Average stood at $127.2 million in 2022, then tumbled by 31.33% to $87.3 million in 2023, then dropped by 27.47% to $63.3 million in 2024, then jumped by 35.67% to $85.9 million in 2025, then gained by 2.87% to $88.4 million in 2026.
- The last three Equity Average figures came in at $88.4 million (Q1 2026), $85.9 million (Q4 2025), and $80.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | 3.50 Bn |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | 783.14 Mn |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | 3.76 Mn |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | 1.01 Bn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | 21.35 Mn |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 19.01 Bn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | 516.41 Mn |
| 10 | XOMA Royalty | 5.52 Mn | -60.56 Mn | - | 88.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 88.41 Mn |
| Dec 31, 2025 | 85.94 Mn |
| Sep 30, 2025 | 80.19 Mn |
| Jun 30, 2025 | 68.52 Mn |
| Mar 31, 2025 | 63.26 Mn |
| Dec 31, 2024 | 63.35 Mn |
| Sep 30, 2024 | 72.38 Mn |
| Jun 30, 2024 | 71.15 Mn |
| Mar 31, 2024 | 65.51 Mn |
| Dec 31, 2023 | 87.33 Mn |
| Sep 30, 2023 | 108.04 Mn |
| Jun 30, 2023 | 112.33 Mn |
| Mar 31, 2023 | 119.27 Mn |
| Dec 31, 2022 | 127.17 Mn |
| Sep 30, 2022 | 132.64 Mn |
| Jun 30, 2022 | 137.44 Mn |
| Mar 31, 2022 | 140.90 Mn |
| Dec 31, 2021 | 126.73 Mn |
| Sep 30, 2021 | 114.08 Mn |
| Jun 30, 2021 | 99.15 Mn |